P450-dependent enzymes as targets for prostate cancer therapy

@article{Coster1996P450dependentEA,
  title={P450-dependent enzymes as targets for prostate cancer therapy},
  author={R. D. Coster and W. Wouters and J. Bruynseels},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={1996},
  volume={56},
  pages={133-143}
}
  • R. D. Coster, W. Wouters, J. Bruynseels
  • Published 1996
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • Metastatic prostate adenocarcinoma is a leading cause of cancer-related deaths among men. First line treatment is primarily aimed at blocking the synthesis and action of androgens. As primary endocrine treatment, androgen deprivation is usually achieved by orchidectomy or LHRH analogues, frequently combined with androgen receptor antagonists in order to block the residual adrenal androgens. However, nearly all the patients will eventually relapse. Available or potential second line therapies… CONTINUE READING
    New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
    • 31

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 88 REFERENCES
    Ketoconazole blocks testosterone synthesis.
    • 362